RT Journal Article
SR Electronic
A1 Sinclair, Heather Q.
T1 Results from the NAVIGATOR Trial
JF MD Conference Express
YR 2010
FD SAGE Publications
VO 10
IS 2
SP 12
OP 13
DO 10.1177/155989771002005
UL http://mdc.sagepub.com/content/10/2/12.2.abstract
AB There is no evidence of cardiovascular benefit that is associated with long-term treatment with nateglinide and valsartan in patients with impaired glucose tolerance and cardiovascular disease (CVD) or CV risk factors. However, valsartan therapy is associated with a reduction in the incidence of diabetes. This article discusses results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research [NAVIGATOR; NCT00097786] Trial.